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Abstract 
 
Background: Randomised trials stopped early for benefit are increasingly common. The 
aims of this study are to use computer simulations to demonstrate how often randomised 
trials can be terminated early for benefit given the proposed effect is true, and to assess 
the impact of early termination on effect estimates.   
 
Methods: Four sets of simulations were conducted with 3, 5, 10, and 20 analyses, 
respectively. Each set included 2000 simulated studies. In each study, a random number 
generator was used to obtain a sample from “treatment” population and another sample 
from “control” population. Relative risks (RR) and Z-scores were compared with the true 
RR and O’Brien-Fleming Z-score boundaries, respectively.   
 
Results: When proposed effect is true and 5 analyses were conducted, about 45% and 
76% of studies were terminated by the third and forth interim analyses, respectively. When 
a specific number of participants were recruited, the proportions of early terminated 
studies were similar regardless of the number of interim analyses. Early terminations 
neither increased the probability of false negative when proposed effect was true, nor 
increased the probability of false positive when null hypothesis was true. However, the 
point effect was over-estimated. 
 
Conclusions and implications: Early termination is a common phenomenon when the 
proposed effect is true and current statistical guidelines are applied. Effect estimates 
among early terminated studies and the summary estimate in a meta-analysis including 
early terminated studies are inflated. Sensitivity analyses should be encouraged in meta-
analyses to assess the bias due to early termination. 
 
Background 
 
Randomised trials stopped early for benefit are increasingly common, and the majority of 
early terminated trials are published in top medical journals (Montori et al., 2005). A 
systematic review found that the number of randomised trials stopped early for benefit has 
more than doubled since 1990 (Montori et al., 2005). The use of the Data Safety & 
Monitoring Committee is increasing (Sydes, Altman, Babiker, Parmar, & Spiegelhalter, 
2004), and is associated with the increasing number of early terminations (Kiri, Tonascia, 
& Meinert, 2004). 
  
Early terminations are generally considered due to an unexpectedly larger than the 
proposed treatment effect (Montori et al., 2005). If the proposed effect is true and interim 
analyses are conducted according to the current statistical guidelines, how often will 
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randomised trials be terminated early? What is the potential impact of early terminations 
on the effect estimates? Answers to these questions are useful for the Data Safety & 
Monitoring Committee and researchers to interpret the effect estimates from early 
terminated studies. Simulation studies use computer intensive procedures to assess the 
appropriateness and accuracy of statistical methods in relation to the known truth (Burton, 
Altman, Royston, & Holder, 2006). In this study, we use simulations to demonstrate how 
often randomised trials can be terminated early and to assess the impact of early 
termination on the effect estimates.  
 
Methods 
 
In our simulations, the true relative risk (RR) is 0.70, and the risks for the outcome of 
interest in the control and treatment populations are 0.172 and 0.12, respectively. A trial 
requires a sample of 1006 subjects in each group to achieve a statistical power of 0.90 
with an alpha level of 0.05. Since we compared the estimated Z-scores with the O’Brien-
Fleming’s Z-score boundaries, the findings can be generalised to trials with different 
effects and risks.  
 
Four sets of simulations were conducted with 3, 5, 10 and 20 analyses, respectively. Each 
set included 2000 simulated datasets. The interim analyses were equally spaced 
proportional to the planned sample size. In each study, a computer random number 
generator was used to obtain one random sample from the control population and another 
from the treatment population.  
 
RRs and their 95% confidence intervals (CI) of treatment versus control and Z-scores were 
calculated. The commonly used O’Brien-Fleming statistical boundaries (O'Brien & Fleming, 
1979) were used to define the stopping cut-offs.  
 
Although in the real world an early termination involves a complicated decision process, for 
the purpose of demonstration, this study focused on early terminations according to 
statistical stopping guidelines. At each interim analysis, the studies with Z-scores outside 
the O’Brien-Fleming boundaries were identified as early terminated studies. Accumulative 
proportions of studies “stopped early” were calculated in two scenarios: 1) the proposed 
effect (RR=0.70) was true, and 2) the null hypothesis (no treatment effect) was true 
(RR=1.0). All analyses were conducted using Stata 10 (StataCorp, 2007).  
 
Results 
 
Scenario 1: the proposed effect is true 
 
Figure 1 (top left) shows the observed Z-score distribution of 2000 simulated studies with 5 
analyses and the proposed RR=0.70. To keep the overall alpha value under 0.05, we used 
the following alpha values to reject the null hypothesis: 0, 0.00039, 0.0037, 0.011 and 
0.021 from the first to fifth analyses, respectively, according to the O’Brien and Fleming 
method (O'Brien & Fleming, 1979). About 45% and 76% studies were terminated by the 
third and forth analyses, respectively. The cumulative probabilities of stopping a trial with 
3, 5, 10 and 20 analyses are shown in Figure 2. The accumulative proportions of early 
terminated studies at a specific time point were similar regardless of the number of interim 
analyses. The majority of the studies were terminated early when the O’Brien-Fleming 
boundaries were used and the proposed treatment effect was true.  
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Figure 1 (Bottom) shows the RRs in five analyses. The horizontal dash line represents the 
true effect (RR = 0.70 in scenario 1 and RR = 1.0 in scenario 2). Those studies stopped 
early for benefit had inflated RRs, particularly from the earlier interim analyses since the 
estimates from those studies stopped early were below the true effect line and further 
away from the non-effect value in scenario 1.   
 
 
 
Mean RRs including both terminated and unterminated studies were about 0.70 at all 
interim analyses in scenario 1. However, if only terminated studies were reported and 
included for a summary effect estimate, RRs were 0.50, 0.62, 0.66 and 0.68 at the second, 
third, forth and fifth analyses, which were 27%, 12%, 6% and 3%, respectively, lower than 
the true value.  
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Among early terminated studies, 26%, 5%, 3% and 3% studies did not include the true 
value in their 95% CIs for the first to fifth analyses, respectively. About 10% studies show 
no significant effects (type II errors), consistent with the power of 0.90.  
 
Scenario 2: the intervention has no effect 
 
When the treatment has no effect, any early terminations are considered as type I errors. 
A small proportion of studies were incorrectly terminated early for either benefit or harm. 
The overall proportion of those showing a significant effect is driven by the predetermined 
alpha level. Consistent with the alpha level of 0.05, about 5% studies showed either 
significantly beneficial or harmful effects.  
 
Conclusions and implications 
 
We have demonstrated several interesting points about interim analyses. First, when the 
proposed treatment effect is true and interim analyses are conducted according to the 
current statistical guidelines, a large proportion of randomised trials will be stopped early 
for benefit. Second, regardless of the number of interim tests conducted, as long as the 
early termination boundaries are predetermined according to the number of interim 
analyses, the probability of stopping early for benefit are similar when a specific proportion 
of subjects are recruited. Third, early terminated studies tend to provide exaggeratedly 
higher effect estimates than the true value. Fourth, 95% CIs from early terminated studies 
can also be misleading because a large proportion of early terminated studies do not 
include the true effect value in their 95% CIs.   
 
When appropriate boundary values for interim analyses are used, early termination will 
neither increase the chance of making a type I error when the null hypothesis is true nor 
increase the chance of making a type II error when the proposed treatment effect is true. 
Therefore, if the objective of a trial is to make a qualitative decision on whether an 
intervention is more efficacious, early termination of a trial is appropriate. However, the 
current debate on early termination is around the accuracy of effect estimates (Bassler et 
al., 2007; Goodman, 2007, 2008; Montori et al., 2005). Bassler et al have shown that most 
systematic reviews and meta-analyses including early stopped trials often fail to consider 
the possible overestimates of effects (Bassler et al., 2007). On the other hand, Goodman 
argues that trials that stop early for benefit are “biased” in the same way as the completed 
trials (Goodman, 2007, 2008). This study demonstrated that the effect estimates from 
interim analyses terminated early can be seriously biased. The earlier is the termination, 
the more extreme is the bias.  
 
Including early terminated studies in a meta-analysis will result in an exaggerated 
summary estimate. The magnitude of bias is influenced by the proportion of early 
terminated trials in the meta-analysis as well as how early those studies have been 
terminated. Researchers of meta-analyses should be encouraged to perform a careful 
sensitivity analysis, in which effect estimates from both competed and early terminated 
studies are compared to assess the potential bias. 
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